预约演示

Teknova opens new manufacturing facility for high-quality reagents

2023-08-10

基因疗法

The new modular manufacturing facility will help bioprocessing and gene therapy companies scale from research to clinical production. Credit: Natali _ Mis/Shutterstock.com.

Alpha Teknova has opened a new modular manufacturing facility in Hollister, California, US, for custom high-quality life sciences reagents.

The facility will help bioprocessing and gene therapy companies scale from research to clinical production.

Alpha Teknovaeports

ReportsProgressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type an... GlobalData

ReportsLOA and PTSR Model - CHM-0201 in Plasma Cell Neoplasm GlobalData

View allCompanies IntelligenceAlpha Teknova IncTeknovaView all

The new facility was previously operational for research-grade production. Following the ISO 13485: 2016 certification, it will now produce GMP-grade high-quality reagents.

A number of 10,000ft² GMP-certified ISO cleanrooms will provide a three-fold increase in overall manufacturing capacity. Expanded formulation, dispensing, warehouse and cleanrooms with increased automation support single-use needs and provide animal-free and endotoxin-controlled environments.

Teknova president and CEO StCHM-0201nstrPlasma Cell Neoplasmm has worked tirelessly over the past two years to build our new GMP-certified production facility here in Hollister and its opening represents a momentous milestone in our company’s evolution.

“We kept hearing from our customers that they wanted a partner who could support them with custom reagent manufacturing as they scale from research through process development and into clinical trials, particularly in batch volumes of less than 2,000 litres.

“We built this facility to do just that – in the city that we’ve called home for almost 20 years – and we look forward to leveraging our facility’s modular manufacturing capabilities to continue supporting our customers throughout various stages of their lifecycle.”

The company also offers customisable solutions to support companies involved in molecular diagnostics, synthetic biology, and cell and gene therapy.

TeknovaGene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free WhitepaperCell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.By Cytiva Thematic

-->

By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构